AR044267A1 - Compuesto intermedio util para la preparacion de pioglitazona - Google Patents
Compuesto intermedio util para la preparacion de pioglitazonaInfo
- Publication number
- AR044267A1 AR044267A1 ARP040101563A ARP040101563A AR044267A1 AR 044267 A1 AR044267 A1 AR 044267A1 AR P040101563 A ARP040101563 A AR P040101563A AR P040101563 A ARP040101563 A AR P040101563A AR 044267 A1 AR044267 A1 AR 044267A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- pioglitazona
- intermediate compound
- compound useful
- pioglitazone
- Prior art date
Links
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960005095 pioglitazone Drugs 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229960004441 tyrosine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
El presente es un intermedio útil para la preparación de pioglitazona. También se refiere a un procedimiento de obtención del nuevo compuesto (1), a partir del producto natural, L-tirosina, en el que se protege el grupo amino en forma de grupo imino aromático, y a un procedimiento de obtención de pioglitazona a partir de dicho intermedio. Reivindicación 1: El compuesto de fórmula (1), en forma de cualquiera de sus dos enantiómeros puros, de mezclas racémicas, o de mezclas enriquecidas en alguno de sus dos enantiómeros, así como sus sales, solvatos e hidratos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200301075A ES2219180B1 (es) | 2003-05-09 | 2003-05-09 | Compuesto intermedio util para la preparacion de pioglitazona. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044267A1 true AR044267A1 (es) | 2005-09-07 |
Family
ID=33427384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101563A AR044267A1 (es) | 2003-05-09 | 2004-05-07 | Compuesto intermedio util para la preparacion de pioglitazona |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7375231B2 (es) |
| EP (1) | EP1623977B1 (es) |
| AR (1) | AR044267A1 (es) |
| AT (1) | ATE377588T1 (es) |
| CA (1) | CA2525190A1 (es) |
| DE (1) | DE602004009917T2 (es) |
| ES (2) | ES2219180B1 (es) |
| PL (1) | PL1623977T3 (es) |
| PT (1) | PT1623977E (es) |
| WO (1) | WO2004099147A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1957476A1 (en) * | 2005-11-23 | 2008-08-20 | AstraZeneca AB | L-alanine derivatives |
| WO2008093065A1 (en) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS |
| WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| WO2012177956A1 (en) * | 2011-06-23 | 2012-12-27 | Metabolic Solutions Development Comapny, Llc | Ppar-sparing compounds for use in the treatment of diabetes and other metabolic diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| JPH08325263A (ja) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規２−アミノ−３−フェニルプロピオン酸誘導体 |
| JP2000344748A (ja) * | 1999-03-29 | 2000-12-12 | Welfide Corp | ３−芳香族置換プロピオン酸またはアクリル酸化合物 |
| AU2002311057A1 (en) * | 2001-04-26 | 2002-11-11 | Leciva, A.S. | Method for obtaining pioglitazone as an antidiabetic agent |
-
2003
- 2003-05-09 ES ES200301075A patent/ES2219180B1/es not_active Expired - Fee Related
-
2004
- 2004-05-04 AT AT04731028T patent/ATE377588T1/de not_active IP Right Cessation
- 2004-05-04 DE DE602004009917T patent/DE602004009917T2/de not_active Expired - Fee Related
- 2004-05-04 ES ES04731028T patent/ES2297415T3/es not_active Expired - Lifetime
- 2004-05-04 PT PT04731028T patent/PT1623977E/pt unknown
- 2004-05-04 US US10/555,659 patent/US7375231B2/en not_active Expired - Fee Related
- 2004-05-04 CA CA002525190A patent/CA2525190A1/en not_active Abandoned
- 2004-05-04 EP EP04731028A patent/EP1623977B1/en not_active Expired - Lifetime
- 2004-05-04 WO PCT/ES2004/070031 patent/WO2004099147A1/es not_active Ceased
- 2004-05-04 PL PL04731028T patent/PL1623977T3/pl unknown
- 2004-05-07 AR ARP040101563A patent/AR044267A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1623977T3 (pl) | 2008-04-30 |
| EP1623977A1 (en) | 2006-02-08 |
| ES2297415T3 (es) | 2008-05-01 |
| WO2004099147A1 (es) | 2004-11-18 |
| US7375231B2 (en) | 2008-05-20 |
| EP1623977B1 (en) | 2007-11-07 |
| CA2525190A1 (en) | 2004-11-18 |
| ATE377588T1 (de) | 2007-11-15 |
| ES2219180A1 (es) | 2004-11-16 |
| DE602004009917D1 (de) | 2007-12-20 |
| PT1623977E (pt) | 2008-01-22 |
| ES2219180B1 (es) | 2006-03-01 |
| US20070083050A1 (en) | 2007-04-12 |
| DE602004009917T2 (de) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200901609A1 (ru) | Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов | |
| EA200900857A1 (ru) | Замещённые 1-(3-пиридинил)пиразол-4-ил-уксусные кислоты, способ их получения и их применение в качестве гербицидов и регуляторов роста растений | |
| UY31084A1 (es) | Compuestos de azaindol para la inhibicion de b-secretasa | |
| EA201100875A1 (ru) | Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов | |
| EA201100189A1 (ru) | Гетероарильные производные в качестве ингибиторов dgat1 | |
| EA200970569A1 (ru) | Применимые в качестве гербицидных соединений пиридопиразиновые производные | |
| ATE540041T1 (de) | Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon | |
| MX2010003849A (es) | Antagonistas de cgrp. | |
| UA87153C2 (ru) | Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы | |
| WO2009065919A3 (de) | Organische verbindungen | |
| BRPI0514201A (pt) | bactéria, e, método para produzir um metabólito útil | |
| WO2009065920A3 (de) | Verbindungen | |
| CY1111733T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| CR10206A (es) | Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| CY1110943T1 (el) | Νεα μεθοδος διαχωρισμου των εναντιομερων του (3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριεν-7-υλ) νιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης | |
| UA106880C2 (uk) | Нові гербіциди | |
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| MX2009011923A (es) | Tetrahidrobenzo-1,4-diazepinas aril- y heteroaril-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina. | |
| PL401473A1 (pl) | Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania | |
| EA200900797A1 (ru) | Способ синтеза производных 3-аминотетрагидрофуран-3-карбоновой кислоты и их применение в качестве лекарственных средств | |
| CO6341477A2 (es) | Compuestos pirrolopirimidincarboxamida, procesos para su producción y composiciones farmaceúticas que comprenden dichos compuestos | |
| DK1948606T3 (da) | 3, 5-disubstituerede phenyl-piperidiner som modulatorer af dopaminneurotransmission | |
| EA200701810A1 (ru) | Производное изоксазолина и новый способ его получения | |
| WO2007020261A3 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |